• ImmunoGen and Jazz collaborate to develop and market ADC products pharmaceutical-technology
    August 31, 2017
    ImmunoGen has entered a collaboration and option agreement to grant exclusive worldwide rights to Jazz Pharmaceuticals for the development and commercialisation of two haematology-related antibody-drug conjugate (ADC) candidates, IMGN779 and IMGN632.
PharmaSources Customer Service